Epionics was founded on 3 November 2008.
Prototypes were developed in collaboration with medics and scientists of the Charité Universitätsmedizin Berlin and subsequently optimized. The market entry of our product Epionics SPINE will commence in April 2011 after concluding the development- and scientific work as well as the effected product approval in accordance to EU-guideline 93/42/EEC.

Company Goal

Our aim is the development and marketing of an instrument for the functional diagnostics in the lumbar spine area, thus closing a decisive gap in the treatment of unspecific back pain.
The strategic company goal is to establish of Epionics SPINE as gold standard for diagnostics and therapy of back pain. As validated instrument for objectifying and evaluating the functional capacity, Epionics SPINE shall provide evidence on back pain for maintaining or respectively restoring the functions as therapy goal.


After providing relevant evidence from the carried out studies Epionics SPINE shall supply specific treatment-guiding statements in relation to measured movement patterns. Furthermore prognostic statements shall also be derived in regard to the success of certain therapeutic measures.

Europäische Union - Europäischer Fonds für regionale Entwicklung. Investition in Ihre Zukunft. Das diesem Bericht zugrunde liegende Vorhaben wurde mit Mitteln des Ministeriums für Wirtschaft des Landes Brandenburg und der EU gefördert. Die Verantwortung für den Inhalt der Veröffentlichung liegt beim Autor.

Epionics Medical GmbH, Beyerstrasse 1, 14469 Potsdam, Germany
Phone: +49 331 2373 05-21, Fax: +49 331 2373 05-10, E-Mail: info@epionics.com